Interdisciplinary Neuroscience Track
PLEASE NOTE: THE IBS Program is no longer accepting students. Students interested in the IBS program should apply through the new Graduate Program in Interdisciplinary Biomedical Sciences. The Clinical and Translational Sciences track listed below has not changed. These pages were left for those students who were accepted into the IBS program before Fall 2016.
Track Leader-Dr. David Davies
Syed Ali, Ph.D.(Pharmacology and Toxicology, and National Center for Toxicological Research)
Helen Benes, Ph.D.(Neurobiology and Developmental Sciences) Web profile
Insect models (fruitflies, mosquitoes) to study molecular basis for regulated gene activity, in response to gender, nutrition, aging and oxidative stress, for insight into human reproductive development, diseases of aging, including cardiac ischemia.
John F. Bowyer, Ph.D.(Pharmacology and Toxicology, and National Center for Toxicological Research)
Identification of gene expression changes as they relate to both neuronal damage and the subsequent repair mechanisms in brain regions histologically observed to be altered by either neurotoxic insults or strong pharmacological stimuli from chemical exposures.
Yuzhi Chen, Ph.D. (Geriatrics, and Neurobiology and Developmental Sciences)Web profile
Protein degradation and signaling in Alzheimer’s disease; stem cell development in neurodegeneration and cancer.
Marie Chow, Ph.D. (Microbiology and Immunology) Web profile
The research program uses RNA viruses to study host physiological processes (such as RNA interference), the cell biology of the virus replication cycle (such as virus entry and exit) and the role of virus-induced immune responses in neurodegenerative diseases (such as post-polio syndrome).
Gerald A. Dienel, Ph.D.(Neurology, and Physiology and Biophysics)
Sherry Ferguson, Ph.D. (Pharmacology and Toxicology)
My research interests are in psychopharmacology, behavioral teratology, and behavioral toxicology. Using nonhuman primates, rodents, and minipigs as models for humans, my work focuses on behavioral endpoints after drug or toxicant exposure. More recently, I have begun a study at Arkansas Children’s Hospital to assess behaviors of children..
Edgar Garcia-Rill, Ph.D.(Neurobiology and Developmental Sciences) Web profile
Disorders of the reticular activating system and sleep, schizophrenia, depression, PTSD, spinal cord injury.
Paul Gottschall, Ph.D.(Pharmacology and Toxicology) Web profile
Research in the laboratory investigates how changes in the structure of the extracellular matrix in the nervous system affects function. Specifically, proteolytic cleavage of extracellular matrix proteins can markedly influence the behavior of neurons and glia, and, depending on the nature of these changes, impact neurological disease in a positive or negative manner.
Sue Griffin, Ph.D.(Geriatrics, and Neurobiology and Developmental Sciences)Web profile
Our interest centers on the influence of neuroinflammatory cytokines, in particular interleukin-1, in the genesis and progression of neurodegenerative diseases such Alzheimer’s disease, Dows syndrome, AIDS, and Parkinson�s disease.
Cynthia (Cindy) J.M. Kane, Ph.D. (Neurobiology and Developmental Sciences) Web profile
Regulation of glial-neuronal interactions in the CNS during normal and abnormal brain development.
Kim E. Light, Ph.D. (Pharmaceutical Sciences) Web profile
My research program is aimed at developing neuronal systems and the alterations to development that result subsequent to exposures to alcohol and other drugs. Our current approach involves immunofluorescence labeling of specific cellular structures, at various developmental times, followed by confocal microscopy analysis of structural neuronal features characteristic of normal developmental as well as specific drug-induced alterations.
S. Michael Owens, Ph.D. (Pharmacology and Toxicology) Web profile
The research program is aimed at discovering monoclonal antibody-based medications for the treatment of medical problems caused by drug abuse.
Merle G. Paule, Ph.D. (Pharmacology and Toxicology, and National Center for Toxicological Research)
Paul L. Prather, Ph.D.(Pharmacology and Toxicology) Web profile
Opioid and cannabinoid receptor signaling mechanisms; cell biology and therapeutic drug development for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS)
Robert D. Skinner, Ph.D.(Neurobiology and Developmental Sciences) Web profile
Spinal cord injury and locomotion pattern generators; midlatency auditory evoked potentials in human brain diseases and the startle response in an animal model.
William Slikker, Ph.D.(Pharmacology and Toxicology, and National Center for Toxicological Research)
William D. Wessinger, Ph.D.(Pharmacology and Toxicology) Web profile
My research interests are in the behavioral pharmacology of drug abuse and the mechanisms of drug dependence and addiction. We are currently conducting research to test antibody-based medications designed to stop or prevent methamphetamine self-administration and/or relapse to methamphetamine use.
Xuming Zhang, Ph.D.(Microbiology and Immunology) Web profile
To elucidate the mechanisms and regulation of coronavirus RNA synthesis, the molecular pathogenesis of coronavirus-induced neurodegenerative diseases, and virus-host cell interactions.
Fang Zheng, Ph.D. (Pharmacology, Interdisciplinary Toxicology) Web profile
Molecular and cellular mechanisms of excitotoxicity related to neurological disorders, with an emphasis on glutamate receptors.